CSIMarket
 


Igc Pharma Inc   (IGC)
Other Ticker:  
 
 

IGC's Capital Expenditures Growth by Quarter and Year

Igc Pharma Inc 's Capital Expenditures results by quarter and year




IGC Capital Expenditures (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter March - 0.48 0.55 0.12
III Quarter December 0.09 0.08 0.05 0.20
II Quarter September 0.06 0.00 0.05 0.31
I Quarter June 0.05 0.16 0.10 0.97
FY   0.20 0.72 0.75 1.60



IGC Capital Expenditures third quarter 2024 Y/Y Growth Comment
Igc Pharma Inc reported Capital Expenditures growth of 8.75% year on year in the third quarter 2024, to $ 0.09 millions, this is lower than Igc Pharma Inc 's recent average Capital Expenditures surge of 1287.12%.

Looking into third quarter 2024 results within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Capital Expenditures growth. While Igc Pharma Inc ' s Capital Expenditures increase of 8.75% ranks overall at the positon no. 290 in the third quarter 2024.




IGC Capital Expenditures ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter March - -12.73 % 358.33 % -83.33 %
III Quarter December 8.75 % 60 % -75 % -88.17 %
II Quarter September - - -83.87 % -64.77 %
I Quarter June -68.75 % 60 % -89.69 % -17.09 %
FY   - -4 % -53.13 % -64.13 %

Financial Statements
Igc Pharma Inc 's third quarter 2024 Capital Expenditures $ 0.09 millions IGC's Income Statement
Igc Pharma Inc 's third quarter 2023 Capital Expenditures $ 0.08 millions Quarterly IGC's Income Statement
New: More IGC's historic Capital Expenditures Growth >>


IGC Capital Expenditures (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter March - 500 % 1000 % -40 %
III Quarter December 45 % - 0 % -35.48 %
II Quarter September 20 % - -50 % -68.04 %
I Quarter June -89.58 % -70.91 % -16.67 % 34.72 %
FY (Year on Year)   - -4 % -53.13 % -64.13 %




Capital Expenditures third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #28
Overall #290

Capital Expenditures Y/Y Growth Statistics
High Average Low
29673.33 % 1287.12 % -126.23 %
(Mar 31 2020)   (Dec 31 2015)
Capital Expenditures third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #12
Healthcare Sector #28
Overall #290
Capital Expenditures Y/Y Growth Statistics
High Average Low
29673.33 % 1287.12 % -126.23 %
(Mar 31 2020)   (Dec 31 2015)

Capital Expenditures by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Igc Pharma Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
28471.43 % 1445.99 % -100 %
(Dec 31 2018)  


IGC's III. Quarter Q/Q Capital Expenditures Comment
Igc Pharma Inc achieved in the III. Quarter 2024 below company average Capital Expenditures jump of 45% quarter on quarter, to $ 0.09 millions.

III. Quarter 2024 Igc Pharma Inc 's performance seem to be a mixed bag, even if below the ordinary growth of 1445.99 %, yet it presents real improvement compare to the % in the III. Quarter 2023

Within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Igc Pharma Inc 's Capital Expenditures growth quarter on quarter, overall rank is 142.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #5
Healthcare Sector #16
Overall #142
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #5
Healthcare Sector #16
Overall #142
Capital Expenditures Q/Q Growth Statistics
High Average Low
28471.43 % 1445.99 % -100 %
(Dec 31 2018)  


IGC's III. Quarter Q/Q Capital Expenditures Comment
Igc Pharma Inc achieved in the III. Quarter 2024 below company average Capital Expenditures jump of 45% quarter on quarter, to $ 0.09 millions.

III. Quarter 2024 Igc Pharma Inc 's performance were a mixed bag, albeit beneath the ordinary, yet it demonstrates real acceleration compare to the % in the III. Quarter 2023 Makayla Lee, Healthcare sector veteran allocated in Boston said.

Within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Igc Pharma Inc 's Capital Expenditures growth quarter on quarter, overall rank is 142.


Igc Pharma Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.67 $ 0.66 $ 0.00 $ 0.00 $ 0.70
Y / Y Capital Expenditures Growth (TTM) - - - - 126.3 %
Year on Year Capital Expenditures Growth Overall Ranking # 32 # 522 # 907 # 2026 # 1883
Seqeuential Capital Expenditures Change (TTM) 0.45 % - - - 5.29 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 290 # 1570 # 963 # 184 # 1635




Cumulative Capital Expenditures growth Comment
Although Igc Pharma Inc 's Annual Capital Expenditures growth year on year were below company's average 1287.12% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 8.75% year on year, from % in Sep 30 2023.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 32, from total ranking in previous quarter at 522.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
29673.33 %
1287.12 %
-126.23 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 12
Healthcare Sector # 5
Overall # 32

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
29673.33 %
1287.12 %
-126.23 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 12
Sector # 28
S&P 500 # 290
Cumulative Capital Expenditures growth Comment
Although Igc Pharma Inc 's Annual Capital Expenditures growth year on year were below company's average 1287.12% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 8.75% year on year, from % in Sep 30 2023.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 32, from total ranking in previous quarter at 522.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
29673.33 %
1287.12 %
-126.23 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 12
Healthcare Sector # 5
Overall # 32

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
29673.33 %
1287.12 %
-126.23 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 12
Sector # 28
S&P 500 # 290




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
IGC's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for IGC's Competitors
Capital Expenditures Growth for Igc Pharma Inc 's Suppliers
Capital Expenditures Growth for IGC's Customers

You may also want to know
IGC's Annual Growth Rates IGC's Profitability Ratios IGC's Asset Turnover Ratio IGC's Dividend Growth
IGC's Roe IGC's Valuation Ratios IGC's Financial Strength Ratios IGC's Dividend Payout Ratio
IGC's Roa IGC's Inventory Turnover Ratio IGC's Growth Rates IGC's Dividend Comparisons



Companies with similar Capital Expenditures jump for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
West Pharmaceutical Services Inc 14.54%$ 14.542 millions
Edwards Lifesciences Corporation14.03%$ 14.029 millions
Pulmonx Corporation13.64%$ 13.636 millions
Phibro Animal Health Corporation11.61%$ 11.610 millions
Halozyme Therapeutics Inc 10.75%$ 10.751 millions
Prestige Consumer Healthcare Inc 10.70%$ 10.704 millions
Encompass Health Corporation10.36%$ 10.362 millions
Select Medical Holdings Corp9.68%$ 9.683 millions
Owens and Minor inc9.51%$ 9.509 millions
Qiagen N v 9.02%$ 9.017 millions
Option Care Health Inc 8.98%$ 8.977 millions
Medpace Holdings Inc 8.04%$ 8.039 millions
Jazz Pharmaceuticals Plc7.72%$ 7.720 millions
Viatris Inc 7.68%$ 7.677 millions
Ptc Therapeutics inc 5.43%$ 5.427 millions
Biocryst Pharmaceuticals Inc 5.32%$ 5.323 millions
Iqvia Holdings Inc 4.68%$ 4.678 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com